Hepatic Arterial Infusion Chemotherapy Plus Lenvatinib and Tislelizumab with or Without Transhepatic Arterial Embolization for Unresectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombus and High Tumor Burden: A Multicenter Retrospective Study.
hepatic arterial infusion chemotherapy
hepatocellular carcinoma
lenvatinib
tislelizumab
transhepatic arterial embolization
Journal
Journal of hepatocellular carcinoma
ISSN: 2253-5969
Titre abrégé: J Hepatocell Carcinoma
Pays: New Zealand
ID NLM: 101674775
Informations de publication
Date de publication:
2023
2023
Historique:
received:
04
05
2023
accepted:
10
07
2023
medline:
3
8
2023
pubmed:
3
8
2023
entrez:
3
8
2023
Statut:
epublish
Résumé
The current therapeutic strategies for high-risk, unresectable hepatocellular carcinoma (HCC) patients demonstrate suboptimal outcomes. This study aimed to assess the clinical efficacy of the combined approach of hepatic arterial infusion chemotherapy (HAIC), lenvatinib, and tislelizumab, either with or without transhepatic arterial embolization (TAE), in managing HCC patients with portal vein tumor thrombus (PVTT) and significant tumor load. In this multicenter retrospective study, we analyzed patients diagnosed with primary, unresectable HCC presenting with PVTT and substantial tumor load who had undergone treatment with HAIC, lenvatinib, and tislelizumab, with or without TAE (referred to as the THLP or HLP group), between January 2019 and February 2022 across four medical centers in China. The outcomes included objective response rate (ORR), disease control rate (DCR), overall survival (OS), and progression-free survival (PFS). The study cohort comprised 100 patients, 50 each in the THLP and HLP groups. The THLP group demonstrated a significantly superior ORR (72% vs 52%, The combination of HAIC, lenvatinib, tislelizumab, and TAE was feasible in HCC patients with PVTT and high tumor burden, with tolerable safety.
Identifiants
pubmed: 37533600
doi: 10.2147/JHC.S417550
pii: 417550
pmc: PMC10390715
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1209-1222Informations de copyright
© 2023 Chen et al.
Déclaration de conflit d'intérêts
All authors have no conflicts of interest to declare.
Références
Clin Cancer Res. 2021 Feb 15;27(4):1003-1011
pubmed: 33087333
Lancet Oncol. 2018 Jul;19(7):940-952
pubmed: 29875066
Am J Cancer Res. 2021 Oct 15;11(10):4711-4724
pubmed: 34765289
Cardiovasc Intervent Radiol. 2003 Mar-Apr;26(2):111-7
pubmed: 12616414
Cancer Immunol Immunother. 2023 Jun;72(6):1365-1379
pubmed: 36633661
J Hepatol. 2017 Jul;67(1):173-183
pubmed: 28323121
Front Oncol. 2021 Feb 25;11:618206
pubmed: 33718175
J Cancer Res Clin Oncol. 2022 Aug;148(8):2115-2125
pubmed: 34453221
Liver Cancer. 2020 Jun;9(3):245-260
pubmed: 32647629
J Clin Oncol. 2023 Jan 1;41(1):117-127
pubmed: 35921605
Hepatol Int. 2021 Jun;15(3):663-675
pubmed: 33877527
J Clin Oncol. 2022 Feb 10;40(5):468-480
pubmed: 34905388
Cell Oncol (Dordr). 2020 Dec;43(6):1203-1214
pubmed: 32797385
Nat Rev Clin Oncol. 2014 Sep;11(9):525-35
pubmed: 25091611
Vasc Cell. 2014 Sep 06;6:18
pubmed: 25197551
Hepatobiliary Pancreat Dis Int. 2004 Aug;3(3):386-90
pubmed: 15313674
J Hepatol. 2020 Feb;72(2):277-287
pubmed: 31954492
J Immunother Cancer. 2021 Sep;9(9):
pubmed: 34593621
Ther Adv Med Oncol. 2021 Mar 25;13:17588359211002720
pubmed: 33854567
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
Liver. 1999 Feb;19(1):25-31
pubmed: 9928762
Signal Transduct Target Ther. 2023 Feb 8;8(1):58
pubmed: 36750721
World J Gastroenterol. 2015 Sep 28;21(36):10443-52
pubmed: 26420971
J Natl Compr Canc Netw. 2019 Apr 1;17(4):302-310
pubmed: 30959462
Cardiovasc Intervent Radiol. 2007 Jan-Feb;30(1):6-25
pubmed: 17103105
Lancet Oncol. 2009 Jan;10(1):25-34
pubmed: 19095497
Invest New Drugs. 2021 Apr;39(2):394-399
pubmed: 33006020
Liver Cancer. 2020 Jun;9(3):338-357
pubmed: 32647635
Lancet. 2017 Jun 24;389(10088):2492-2502
pubmed: 28434648
BMC Cancer. 2018 Jan 29;18(1):101
pubmed: 29378532
Radiology. 2022 May;303(2):455-464
pubmed: 35103539
Hepatobiliary Surg Nutr. 2020 Aug;9(4):452-463
pubmed: 32832496
Eur J Cancer. 2022 Oct;174:68-77
pubmed: 35981413
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Nat Rev Cancer. 2010 Jul;10(7):505-14
pubmed: 20574450
Future Oncol. 2020 Nov;16(32):2587-2589
pubmed: 32772560
Lancet. 2018 Mar 24;391(10126):1163-1173
pubmed: 29433850
J Vasc Interv Radiol. 2007 Oct;18(10):1249-57
pubmed: 17911515
Semin Liver Dis. 2010 Feb;30(1):52-60
pubmed: 20175033
JAMA Oncol. 2019 Jul 1;5(7):953-960
pubmed: 31070690
JGH Open. 2019 Dec 13;4(3):477-483
pubmed: 32514457
Liver Cancer. 2021 Jun;10(3):181-223
pubmed: 34239808
Int J Mol Sci. 2022 Sep 26;23(19):
pubmed: 36232663
N Engl J Med. 2020 May 14;382(20):1894-1905
pubmed: 32402160
Lancet Oncol. 2022 Sep;23(9):1167-1179
pubmed: 35908558
J Clin Oncol. 2020 Sep 10;38(26):2960-2970
pubmed: 32716739
Expert Rev Gastroenterol Hepatol. 2022 Apr;16(4):333-339
pubmed: 35403533
Expert Opin Investig Drugs. 2022 Apr;31(4):361-369
pubmed: 34798793
BMC Cancer. 2021 Oct 19;21(1):1126
pubmed: 34670506
J Clin Oncol. 2022 Jan 10;40(2):150-160
pubmed: 34648352
Hepatology. 2018 Jan;67(1):358-380
pubmed: 28130846
Immunotherapy. 2021 Dec;13(17):1395-1405
pubmed: 34607482
J Vasc Interv Radiol. 2007 May;18(5):639-45
pubmed: 17494846